Prestige Biopharma eyes at least 1.8t won valuation in Korean IPO

Biotech firm also plans to expand its headcount to about 300 in next five years


SINGAPORE-BASED Prestige Biopharma expects an implied market capitalisation of between 1.8 trillion won and 1.93 trillion won (S$2.2 billion to S$2.3 billion) in its upcoming initial public offering (IPO) on the Korea Exchange (KRX), the company told The Business Times.